Answers are grounded in this paper and cite their sources.
The pharmaceutical industry has long been one of the most innovative industries and, unlike industries such as computers and aircraft, has remained relatively unconcentrated. In recent years, however, there have been contrasting industry developments that could have far-reaching, long-run effects on the industry's structure. This paper examines the impact of the entry of new biotechnology firms, the increasing real cost of innovation, and the recent important mergers among leading firms. Also, a regression analysis reveals disproportionately high innovative contributions from both new biotechnology firms and the very largest multinational pharmaceutical firms.
No takes yet. Share an insight, caveat, or question.
Grabowski et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: